Clinical Trial Update: Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 trial of NGM707 in combination with pembrolizumab for advanced or metastatic solid tumors, including colorectal cancer, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• NGM707 (NGM707)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: CRC | Phase 2 | Status: WITHDRAWN